In primary T cells, TNFRSF25 agonists enhance survival, proliferation, and effector functions, including cytokine release and targeted cell killing. These effects require prior TCR engagement.

Immunocore has secured a piece of biotech industry history, becoming the first company to get an FDA approval for a cancer therapeutic based on T cell receptor (TCR) technology. The US regulator ...

Invikafusp alfa is Marengo's first-in-class, dual T cell agonist with a bi-specific antibody ... develops novel TCR-targeting antibodies that selectively modulate common and disease-specific ...

IMA203 is an autologous, engineered T-cell receptor T-cell therapy (TCR T) that targets PRAME, an intracellular protein displayed as a peptide antigen on the surface of multiple solid tumors via ...

We show here active clustering of TCR–MHC molecules at the immune synapse ... Peptide OVA 323–339 (ISQAVHAA HAEINEAGR) and analogs OVA 331H-A (weak agonist; ISQAVHAAAAEINEAGR) and OVA336E ...

Zelluna Reaches Major Milestone with Manufacturing Process Established in Preparation for Clinical Entry of ZI-MA4-1, its Novel TCR-NK Therapy Targeting Solid Tumours Oslo, Norway, 22 April 2025 – ...